Company / Cash & Equivalents
Axsome Therapeutics, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$322.9M
FY2025
5-year range
$86.5M / $386.2M
FY2021-FY2025
Trend
+2.4%
vs FY2024
Sector context
#60 of 207
Health Care
What the data says
At $323M, Axsome Therapeutics, Inc.'s cash & equivalents ranks #60 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 7 years, ranging from $86M in FY2021 to $386M in FY2023.
Based on SEC 10-K filings.
$323M in FY2025 with a 5-year CAGR of +11.9%.
Declined from $386M to $323M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +17.2%
- 5-Year CAGR
- +11.9%
- 10-Year CAGR
- -
Sector benchmark
#60 of 207 in Health CareTop 29% of 207This company $322.9M Sector average $669.5M
▼
-51.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 2.4% year-over-year.
- Ranks #60 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $322.9M | +2.4% |
| FY2024 | $315.4M | -18.3% |
| FY2023 | $386.2M | +92.3% |
| FY2022 | $200.8M | +132.3% |
| FY2021 | $86.5M | -53.0% |
| FY2020 | $183.9M | -16.4% |
| FY2019 | $220.0M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026